What sector does Astrazeneca Pharma Ind Lt belong to?

Astrazeneca Pharma Ind Lt operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of ASTRAZEN?

As of the latest available quote, ASTRAZEN traded at ₹6,764.50. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of ASTRAZEN?

Astrazeneca Pharma Ind Lt has a price-to-earnings (P/E) ratio of about 99.99. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of ASTRAZEN?

The market capitalisation of Astrazeneca Pharma Ind Lt is approximately ₹16,911 Cr.

Is Astrazeneca Pharma Ind Lt profitable?

For its latest reported financial year, Astrazeneca Pharma Ind Lt recorded a net profit margin of about 8.26%.

Does ASTRAZEN pay a dividend?

Astrazeneca Pharma Ind Lt does not currently show a dividend yield in our data.

What is the return on equity (ROE) of ASTRAZEN?

Astrazeneca Pharma Ind Lt has a return on equity (ROE) of about 23.30%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of ASTRAZEN?

Over the past 52 weeks, ASTRAZEN has traded between a low of ₹6,750.00 and a high of ₹9,849.50.

Astrazeneca Pharma Ind Lt

ASTRAZEN NSE Healthcare Pharmaceuticals

₹6,764.50

-1.40%

Delayed · cached 15 min

Fair value analysis

ASTRAZEN

Astrazeneca Pharma Ind Lt

₹6,860.50

Close used for this calculation

₹2,052.78Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

44/100

Profitability19/25

Returns8/25

Balance Sheet11/25

Efficiency6/25

Growth12/25

Average

Quality radar

Consensus fair value

₹2,052.78

Above FV

▼ -70.1% against the close used

Model range ₹743.25 – ₹2,677.86

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹743.25Fair value₹2,052.78Bull₹2,677.86

FairClose

52-week traded range

52W low ₹6,860.5052W high ₹9,827.50

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Astrazeneca Pharma Ind Lt closed at ₹6,860.50, 234.2% above the consensus fair value of ₹2,052.78 drawn from 8 valuation models.

Financial DNA score 44/100 — Average. P/E of 97.5x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹1,488.87

-78.3%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹743.25

-89.2%

√(22.5 × EPS × BVPS)

EPS=75.01, BVPS=327.31 · outside Graham range (P/E 97.5, P/B 21) — asset-light, treat as a rough floor

P/E Fair Value

₹2,677.86

-61.0%

EPS × 35.7x (sector P/E)

EPS=75.01, Sector P/E=35.7x

Peter Lynch (PEG)

₹1,770.24

-74.2%

EPS × Growth% (PEG = 1 is fair)

EPS=75.01, g=23.6%

EV/EBITDA

₹2,079.94

-69.7%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=2.91B

Book Value (P/B)

₹1,415.63

-79.4%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=327.31, ROE=23.3%, g=6%, r=10%

Reverse DCF

₹6,860.50

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 27.9% | Historical: 23.6%

Margin of Safety

₹1,227.50

-82.1%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=1636.66, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer